Your browser is no longer supported. Please, upgrade your browser.
ARTL Artelo Biosciences, Inc. daily Stock Chart
Artelo Biosciences, Inc.
Index- P/E- EPS (ttm)-1.24 Insider Own19.20% Shs Outstand3.43M Perf Week-1.97%
Market Cap4.10M Forward P/E- EPS next Y-1.64 Insider Trans0.00% Shs Float2.49M Perf Month-6.39%
Income-3.90M PEG- EPS next Q-0.40 Inst Own0.40% Short Float0.25% Perf Quarter23.27%
Sales- P/S- EPS this Y-336.10% Inst Trans- Short Ratio0.02 Perf Half Y-51.18%
Book/sh1.08 P/B1.15 EPS next Y0.60% ROA-89.20% Target Price- Perf Year-70.36%
Cash/sh0.61 P/C2.05 EPS next 5Y- ROE-108.40% 52W Range0.61 - 4.99 Perf YTD-53.89%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.05% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low104.10% ATR0.16
Employees3 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)46.70 Volatility7.73% 12.39%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.30 Prev Close1.21
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume269.44K Price1.25
Recom3.00 SMA20-4.85% SMA50-3.88% SMA200-27.46% Volume81,668 Change2.89%
Jun-29-20 08:30AM  
Jun-03-20 09:30AM  
May-12-20 09:30AM  
May-06-20 09:09AM  
Apr-14-20 08:30AM  
Mar-23-20 09:00AM  
Mar-02-20 09:07AM  
Feb-24-20 09:00AM  
Feb-03-20 11:42AM  
Jan-29-20 09:00AM  
Jan-14-20 08:00AM  
Dec-09-19 08:30AM  
Nov-25-19 08:00AM  
Nov-18-19 08:30AM  
Nov-14-19 09:00AM  
Oct-29-19 08:30AM  
Oct-22-19 09:00AM  
Sep-18-19 08:00AM  
Sep-11-19 09:00AM  
Sep-04-19 01:34PM  
Jul-15-19 04:01PM  
Jul-10-19 07:23AM  
Jun-25-19 01:00PM  
May-08-19 04:05PM  
Jan-03-19 07:00AM  
Oct-09-18 08:00AM  
Jul-03-18 08:00AM  
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system and related signaling pathways. Its product pipeline includes ART27.13, a cannabinoid agonist for the treatment of anorexia associated with cancer; ART12.11, a CBD cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a FABP5 inhibitor for prostate and breast cancer treatment. It has research and worldwide commercial license agreement with Stony Brook University for FABP5 platform for the development of lead cancer, pain, and inflammation compounds. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is headquartered in La Jolla, California.